Aurinia Pharmaceuticals (AUPH) Tops Q1 EPS by 5c, provides guidance

Aurinia Pharmaceuticals (NASDAQ: AUPH) reported Q1 EPS of $0.16, $0.05 better than the analyst estimate of $0.11. Revenue for the quarter came in at $62.5 million versus the consensus estimate of $62.55 million.

GUIDANCE:

Aurinia Pharmaceuticals sees FY2025 revenue of $250-260 million, versus the consensus of $258.6 million.

For earnings history and earnings-related data on Aurinia Pharmaceuticals (AUPH) click here.

You May Also Be Interested In

• Morgan Stanley upgrades CDW on stronger AI-driven server demand
• Zeta Surgical begins TMS navigation treatments at Hope Therapeutics clinics
• Daiwa Securities Downgrades JD.com, Inc (JD) to Hold